First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial

BACKGROUND: Many patients with advanced non-small-cell lung cancer (NSCLC) receive only active supportive care because of poor performance status or presence of several comorbidities. We investigated whether erlotinib improves clinical outcome in these patients. METHODS: TOPICAL was a double-blind,...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Lee, Siow Ming, Khan, Iftekhar, Upadhyay, Sunil, Lewanski, Conrad, Falk, Stephen, Skailes, Geraldine, Marshall, Ernie, Woll, Penella J, Hatton, Matthew, Lal, Rohit, Jones, Richard, Toy, Elizabeth, Chao, David, Middleton, Gary, Bulley, Sue, Ngai, Yenting, Rudd, Robin, Hackshaw, Allan, Boshoff, Chris
Формат: Artigo
Язык:Inglês
Опубликовано: Lancet Pub. Group 2012
Предметы:
Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3488187/
https://ncbi.nlm.nih.gov/pubmed/23078958
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(12)70412-6
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы